Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
455 studies found for:    Lipid Storage Diseases
Show Display Options
Rank Status Study
21 Recruiting Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children
Conditions: Mucopolysaccharidosis Type I (MPS I);   Mucopolysaccharidosis Type II (MPS II);   Mucopolysaccharidosis Type III (MPS III);   Mucopolysaccharidosis Type VI (MPS VI);   Krabbe Disease
22 Recruiting National Lysosomal Acid Lipase Deficiency Study
Condition: Cholesteryl Ester Storage Disease
23 Terminated Natural History Study of Children With Metachromatic Leukodystrophy
Conditions: Lipid Metabolism Disorders;   Metachromatic Leukodystrophy (MLD);   Nervous System Diseases;   Brain Diseases;   Central Nervous System Diseases;   Demyelinating Diseases;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Sphingolipidoses;   Hereditary Central Nervous System Demyelinating Diseases;   Metabolic Inborn Brain Diseases;   Lysosomal Storage Diseases;   Metabolic Diseases;   Sulfatidosis
24 Completed Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn
Conditions: Infant, Newborn, Diseases;   Other Lipid Storage Disorders
Interventions: Dietary Supplement: Lutein drops;   Dietary Supplement: Glucose drops
25 Recruiting Biomarker for Wolman Disease
Conditions: Wolman Disease;   Acid Lipase Deficiency;   Acid Cholesteryl Ester Hydrolase Deficiency, Wolman Type;   Cholesterol Ester Storage Disease
26 Active, not recruiting
Has Results
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
Conditions: Cholesterol Ester Storage Disease(CESD);   Lysosomal Acid Lipase Deficiency
Intervention: Drug: SBC-102 (sebelipase alfa)
27 Completed An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: Replagal agalsidase alfa;   Drug: Replagal
28 Completed An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
29 Recruiting Lipidomics and Functional Analyses of Platelets in Fabry Disease
Condition: Fabry Disease
30 Completed An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
Conditions: Cholesterol Ester Storage Disease(CESD);   Lysosomal Acid Lipase Deficiency
31 Completed Wolman/CESD Natural History Chart Review and Longitudinal Follow-Up
Conditions: Wolman Disease;   Cholesterol Ester Storage Disease;   Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Intervention: Other: There are no interventions in this study.
32 Withdrawn Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction
Condition: Mixed Hyperlipoproteinemia
Interventions: Dietary Supplement: Pro-Omega LDL;   Other: Placebo
33 Completed A Pilot Study to Evaluate the Lipid Effects of TRIA-662
Conditions: Hypertriglyceridemia;   Mixed Hyperlipidemia
Interventions: Drug: TRIA-662;   Drug: Placebo
34 Unknown  Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 10mg, fenofibric acid 135mg;   Drug: atorvastatin 20mg
35 Completed
Has Results
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: SCH 900271 15mg;   Drug: SCH 900271;   Drug: Placebo
36 Completed
Has Results
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Condition: Mixed Hyperlipidemia
Interventions: Drug: MK-0524A;   Drug: Atorvastatin;   Drug: Simvastatin
37 Completed Lipid Efficacy Study (0524B-022)(COMPLETED)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant (+) simvastatin;   Drug: Comparator: niacin (+) laropiprant;   Drug: Comparator: simvastatin
38 Completed Lipid Efficacy/Tolerability Study (0524A-020)
Conditions: Primary Hypercholesterolaemia;   Mixed Hyperlipidaemia
Interventions: Drug: niacin (+) laropiprant;   Drug: ER-niacin
39 Terminated Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Condition: Mixed Hyperlipidemia
Interventions: Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
40 Completed A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
Conditions: Hyperlipidemia;   Hypercholesterolemia;   Hypertriglyceridemia
Intervention: Drug: ezetimibe (+) simvastatin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years